OH2 Oncolytic Viral Therapy in Solid Tumors
Key facts
- Who runs it
- Binhui Biopharmaceutical Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 300 people, planned
- Started
- 2 Apr 2019
- Planned end
- 30 Aug 2025
- Type of study
- Interventional
- Treatments tested
- OH2 injection, with or without irinotecan or HX008
- Record updated
- 20 December 2024
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (21)Hide the full registry criteria
Who can take part
- Histologically or cytologically confirmed unresectable or recurrent/metastatic solid tumors
- The patient must have failed the standard treatment (due to either disease progression or intolerable toxicity) or the standard of care had not been established for the specific condition
- Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
- Eastern Collaborative Oncology Group (ECOG) Performance Status ≤ 1
- Life expectancy >3 months
- The patient must have at least one tumor site appropriate for intratumoral injection
- Adequate organ function
- Participants of reproductive potential must be willing to use adequate contraception for the course of the study until 3 months after the last dose of any of the drugs in the study
- Participants with a history of HSV infection must have recovered at least 3 months before the study
- Willing and able to provide written informed consent and comply with the requirements of the study
Who cannot take part
- Uncontrolled concurrent illness including, but not limited to, severe cardiac disease, cerebralvascular disease, uncontrolled diabetes, uncontrolled hypertension, ongoing or active systemic infection, active peptic ulcer disease
- Patients who are receiving any other investigational agents
- Concurrent medical condition requiring the use of cortisol (>10mg/day prednisone or equivalent dose) or other systematic immunosuppressive medications within 14 days before the study treatment, except for inhalation or topical corticosteroids no more than 10 mg/day prednisone or equivalent
- Active infection or an unexplained fever > 38.5°C
- Known Human Immunodeficiency Virus (HIV) infection, active Hepatitis B or Hepatitis C infection
- Known immediate or delayed hypersensitivity reaction to HSV
- Previous malignancy within 5 years prior to study entry
- Patients with any active autoimmune disease or history of autoimmune disease
- Familial, sociological or geographical conditions that, in the judgment of the investigator, do not permit compliance with the protocol
- Central nervous system (CNS) metastases with clinical symptoms
- Pregnant or lactating female
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Solid tumor or gastrointestinal cancer
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This phase I/II study evaluates the safety and efficacy of OH2 as single agent or in combination with HX008, an anti-PD-1 antibody, in patients with malignant solid tumors (gastrointestinal cancers, head and neck cancers, soft tissue sarcomas).
Read full original descriptionShow less
OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response.
The group in the trial
- Dose escalation and dose expansionTreatment being tested
A 3+3 dose-escalation strategy is used in the phase 1 part and 3 dose levels (10e6, 10e7 and 10e8 CCID50/mL) of OH2 are assessed as single agent and in combination with HX008. The recommended dose levels are then determined and adopted in the phase 2 part for dose-expansion. In the phase 2 dose-expansion part, OH2 will be delivered as single agent in cohort 1, in combination with irinotecan in cohort 2, in combination with HX008 in cohort 3 and 4. There are no comparator arms for these cohorts.
Treatment: OH2 injection, with or without irinotecan or HX008
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase I/II Study of OH2 Injection, an Oncolytic Type 2 Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor, in Malignant Solid Tumors
- Criteria questions
- Built from NCT03866525, who can take part
- Publications
- NK cell tumor therapy modulated by UV-inactivated oncolytic herpes simplex virus type 2 and checkpoint inhibitors.Translational research : the journal of laboratory and clinical medicine, 2022
- Record updated
- 20 December 2024